AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 211 min read$UTHR

ROTHBLATT MARTINE A sold $4.7M of UTHR (indirect holdings)

ROTHBLATT MARTINE A (Chairperson & CEO) sold 9,500 indirectly-held shares of UNITED THERAPEUTICS Corp (UTHR) at an average of $494.79 ($492.91–$498.25, $4.70M total) across 6 trades on 2026-09-18 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · ROTHBLATT MARTINE A
Published Sep 21, 2026, 8:44 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 21, 2026, 9:34 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$UTHR
Bearish
medium confidence
Mentioned
$UTHR
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$UTHRBearishMed
01

Why it matters

The $4.7M sale reduces insider ownership but leaves the CEO with a substantial stake, suggesting continued confidence.

02

Market read

Primary insider sale news; modest short‑term trading relevance.

03

What to watch

Rothblatt's 10b5‑1 plan may have been set months ago; the sale does not reflect current sentiment.

Relevance 5/10Novelty 7/10Timing: post‑market 2026‑09‑18

Background

Form 4 filings disclose insider transactions; a sale by a CEO is closely watched by investors.

Company-level read

Ticker impact

$UTHRBearishMedium confidence
Context

CEO Martine Rothblatt sold 9,500 shares for $4.7M via a 10b5‑1 plan, reducing her stake to 324,443 shares.

Expected impact

Possible modest downside of 2‑4% over the next few days as the market digests the sale.

Evidence & confidence

A $4.7M sale by the chairperson is material but not large enough to trigger a major move; market typically reacts modestly to such insider disposals.

Market effects

Sector

Minimal impact on the biotech/biopharma sector; other companies unlikely to be affected.

Regional

U.S. market only; no regional ripple.

Global

Low; the filing is company‑specific.

Counterpoint

What could challenge this read

The sale could be a routine liquidity event under a pre‑arranged plan, not a negative signal.

Key entities

  • Company
    United Therapeutics Corp

    Biopharma company developing organ transplantation and pulmonary therapies.

  • Executive
    Martine Rothblatt

    Chairperson & CEO of United Therapeutics.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

UTHR insider trading history →

Related articles

OCT 28
$UTHRMed

United Therapeutics Receives FDA Clearance to Begin Clinical Trial of Inhaled PAH Treatment

United Therapeutics (UTHR) received FDA clearance to start clinical trials for Treprostinil-Iloprost SMI, an inhaled treatment for pulmonary arterial hypertension (PAH). The phase 1 trial will assess safety and tolerability. The therapy aims to address symptom flare-ups between maintenance doses. UTHR plans a phase 2 trial in 2027 if initial results are positive. PAH affects around 500,000 people globally.

finance.yahoo.com2 min
OCT 28
$UTHRMed

FDA clears a trial of a two-drug inhaler that could be the first as-needed therapy for lung artery disease.

The FDA approved a trial for Treprostinil-Iloprost SMI, a potential first as-needed inhaler therapy for pulmonary arterial hypertension (PAH). United Therapeutics plans a phase 1 study in 2026, with a phase 2 study in PAH patients anticipated in 2027. The therapy combines treprostinil and iloprost, aiming to provide episodic symptom relief. United Therapeutics aims to expand its PAH treatment portfolio.

stocktitan.net2 min